Cargando…
Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification
Luteolin, a natural flavone compound, exists in a variety of fruits and vegetables, and its anticancer effect has been shown in many studies. However, its use in glioma treatment is hampered due to the fact that the underlying mechanism of action has not been fully explored. Therefore, we elucidated...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643232/ https://www.ncbi.nlm.nih.gov/pubmed/34873410 http://dx.doi.org/10.1155/2021/7765658 |
_version_ | 1784609841130504192 |
---|---|
author | Huang, Renxuan Dong, Rui Wang, Nan Lan, Beiwu Zhao, Hongyang Gao, Yufei |
author_facet | Huang, Renxuan Dong, Rui Wang, Nan Lan, Beiwu Zhao, Hongyang Gao, Yufei |
author_sort | Huang, Renxuan |
collection | PubMed |
description | Luteolin, a natural flavone compound, exists in a variety of fruits and vegetables, and its anticancer effect has been shown in many studies. However, its use in glioma treatment is hampered due to the fact that the underlying mechanism of action has not been fully explored. Therefore, we elucidated the potential antiglioma targets and pathways of luteolin systematically with the help of network pharmacology and molecular docking technology. The druggability of luteolin, including absorption, excretion, distribution, and metabolism, was assessed via the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). The potential targets of luteolin and glioma were extracted from public databases, and the intersecting targets between luteolin and glioma were integrated and visualized by a Venn diagram. In addition, GO and KEGG pathway analysis was engaged in Metascape. The network of the luteolin-target-pathway was visualized by Cytoscape. Ultimately, the interactions between luteolin and predicted key targets were confirmed by Discovery studio software. According to the ADME results, luteolin shows great potential for development into a drug. 4860 glioma-associated targets and 280 targets of luteolin were identified, of which 205 were intersection targets. 6 core targets of luteolin against glioma, including AKT1, JUN, ALB, MAPK3, MAPK1, and TNF, were identified via PPI network analysis of which AKT1, JUN, ALB, MAPK1, and TNF harbor diagnostic value. The biological processes of luteolin are mainly involved in the response to inorganic substances, response to oxidative stress, and apoptotic signaling pathway. The essential pathways of luteolin against glioma involve pathways in cancer, the PI3K-Akt signaling pathway, the TNF signaling pathway, and more. Meanwhile, luteolin's interaction with six core targets was verified by molecular docking simulation and its antiglioma effect was verified by in vitro experiments. This study suggests that luteolin has a promising potential for development into a drug and, moreover, it displays preventive effects against glioma by targeting various genes and pathways. |
format | Online Article Text |
id | pubmed-8643232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-86432322021-12-05 Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification Huang, Renxuan Dong, Rui Wang, Nan Lan, Beiwu Zhao, Hongyang Gao, Yufei Evid Based Complement Alternat Med Research Article Luteolin, a natural flavone compound, exists in a variety of fruits and vegetables, and its anticancer effect has been shown in many studies. However, its use in glioma treatment is hampered due to the fact that the underlying mechanism of action has not been fully explored. Therefore, we elucidated the potential antiglioma targets and pathways of luteolin systematically with the help of network pharmacology and molecular docking technology. The druggability of luteolin, including absorption, excretion, distribution, and metabolism, was assessed via the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). The potential targets of luteolin and glioma were extracted from public databases, and the intersecting targets between luteolin and glioma were integrated and visualized by a Venn diagram. In addition, GO and KEGG pathway analysis was engaged in Metascape. The network of the luteolin-target-pathway was visualized by Cytoscape. Ultimately, the interactions between luteolin and predicted key targets were confirmed by Discovery studio software. According to the ADME results, luteolin shows great potential for development into a drug. 4860 glioma-associated targets and 280 targets of luteolin were identified, of which 205 were intersection targets. 6 core targets of luteolin against glioma, including AKT1, JUN, ALB, MAPK3, MAPK1, and TNF, were identified via PPI network analysis of which AKT1, JUN, ALB, MAPK1, and TNF harbor diagnostic value. The biological processes of luteolin are mainly involved in the response to inorganic substances, response to oxidative stress, and apoptotic signaling pathway. The essential pathways of luteolin against glioma involve pathways in cancer, the PI3K-Akt signaling pathway, the TNF signaling pathway, and more. Meanwhile, luteolin's interaction with six core targets was verified by molecular docking simulation and its antiglioma effect was verified by in vitro experiments. This study suggests that luteolin has a promising potential for development into a drug and, moreover, it displays preventive effects against glioma by targeting various genes and pathways. Hindawi 2021-11-27 /pmc/articles/PMC8643232/ /pubmed/34873410 http://dx.doi.org/10.1155/2021/7765658 Text en Copyright © 2021 Renxuan Huang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Huang, Renxuan Dong, Rui Wang, Nan Lan, Beiwu Zhao, Hongyang Gao, Yufei Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification |
title | Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification |
title_full | Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification |
title_fullStr | Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification |
title_full_unstemmed | Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification |
title_short | Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification |
title_sort | exploring the antiglioma mechanisms of luteolin based on network pharmacology and experimental verification |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643232/ https://www.ncbi.nlm.nih.gov/pubmed/34873410 http://dx.doi.org/10.1155/2021/7765658 |
work_keys_str_mv | AT huangrenxuan exploringtheantigliomamechanismsofluteolinbasedonnetworkpharmacologyandexperimentalverification AT dongrui exploringtheantigliomamechanismsofluteolinbasedonnetworkpharmacologyandexperimentalverification AT wangnan exploringtheantigliomamechanismsofluteolinbasedonnetworkpharmacologyandexperimentalverification AT lanbeiwu exploringtheantigliomamechanismsofluteolinbasedonnetworkpharmacologyandexperimentalverification AT zhaohongyang exploringtheantigliomamechanismsofluteolinbasedonnetworkpharmacologyandexperimentalverification AT gaoyufei exploringtheantigliomamechanismsofluteolinbasedonnetworkpharmacologyandexperimentalverification |